257 related articles for article (PubMed ID: 29194547)
1. Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.
Moodie Z; Juraska M; Huang Y; Zhuang Y; Fong Y; Carpp LN; Self SG; Chambonneau L; Small R; Jackson N; Noriega F; Gilbert PB
J Infect Dis; 2018 Feb; 217(5):742-753. PubMed ID: 29194547
[TBL] [Abstract][Full Text] [Related]
2. Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America.
Carpp LN; Fong Y; Bonaparte M; Moodie Z; Juraska M; Huang Y; Price B; Zhuang Y; Shao J; Zheng L; Chambonneau L; Small R; Sridhar S; DiazGranados CA; Gilbert PB
PLoS One; 2020; 15(6):e0234236. PubMed ID: 32542024
[TBL] [Abstract][Full Text] [Related]
3. Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.
Reynales H; Carrasquilla G; Zambrano B; Cortés S M; Machabert T; Jing J; Pallardy S; Haney O; Faccini M; Quintero J; Noriega F
Pediatr Infect Dis J; 2020 Apr; 39(4):e30-e36. PubMed ID: 32040014
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials.
Huang Y; Williamson BD; Moodie Z; Carpp LN; Chambonneau L; DiazGranados CA; Gilbert PB
J Infect Dis; 2022 Jan; 225(2):332-340. PubMed ID: 34174082
[TBL] [Abstract][Full Text] [Related]
5. Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.
Gilbert PB; Huang Y; Juraska M; Moodie Z; Fong Y; Luedtke A; Zhuang Y; Shao J; Carpp LN; Jackson N; Chambonneau L; Bouckenooghe A; Zambrano B; Frago C; Pallardy S; Noriega F
Am J Trop Med Hyg; 2019 Jul; 101(1):164-179. PubMed ID: 31115304
[TBL] [Abstract][Full Text] [Related]
6. Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.
Olivera-Botello G; Coudeville L; Fanouillere K; Guy B; Chambonneau L; Noriega F; Jackson N;
J Infect Dis; 2016 Oct; 214(7):994-1000. PubMed ID: 27418050
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
Forrat R; Dayan GH; DiazGranados CA; Bonaparte M; Laot T; Capeding MR; Sanchez L; Coronel DL; Reynales H; Chansinghakul D; Hadinegoro SRS; Perroud AP; Frago C; Zambrano B; Machabert T; Wu Y; Luedtke A; Price B; Vigne C; Haney O; Savarino SJ; Bouckenooghe A; Noriega F
Clin Infect Dis; 2021 Sep; 73(6):1003-1012. PubMed ID: 33822015
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
[TBL] [Abstract][Full Text] [Related]
9. Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials.
Juraska M; Magaret CA; Shao J; Carpp LN; Fiore-Gartland AJ; Benkeser D; Girerd-Chambaz Y; Langevin E; Frago C; Guy B; Jackson N; Duong Thi Hue K; Simmons CP; Edlefsen PT; Gilbert PB
Proc Natl Acad Sci U S A; 2018 Sep; 115(36):E8378-E8387. PubMed ID: 30127007
[TBL] [Abstract][Full Text] [Related]
10. Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries.
Huang Y; Moodie Z; Juraska M; Fong Y; Carpp LN; Chambonneau L; Coronel DL; Dayan GH; DiazGranados CA; Gilbert PB
Trans R Soc Trop Med Hyg; 2021 Jul; 115(7):750-763. PubMed ID: 33369671
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia.
Qi L; Sun Y; Juraska M; Moodie Z; Magaret CA; Heng F; Carpp LN; Gilbert PB
Vaccine; 2022 Sep; 40(41):5912-5923. PubMed ID: 36068106
[TBL] [Abstract][Full Text] [Related]
12. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.
Vigne C; Dupuy M; Richetin A; Guy B; Jackson N; Bonaparte M; Hu B; Saville M; Chansinghakul D; Noriega F; Plennevaux E
Hum Vaccin Immunother; 2017 Sep; 13(9):2004-2016. PubMed ID: 28598256
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a tetravalent dengue vaccine in children in Latin America.
Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
[TBL] [Abstract][Full Text] [Related]
14. Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.
Dayan GH; Langevin E; Forrat R; Zambrano B; Noriega F; Frago C; Bouckenooghe A; Machabert T; Savarino S; DiazGranados CA
Vaccine; 2020 Sep; 38(41):6472-6477. PubMed ID: 32773243
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus.
Dayan GH; Langevin E; Gilbert PB; Wu Y; Moodie Z; Forrat R; Price B; Frago C; Bouckenooghe A; Cortes M; Noriega F; DiazGranados CA
Vaccine; 2020 Apr; 38(19):3531-3536. PubMed ID: 32204943
[TBL] [Abstract][Full Text] [Related]
16. Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial.
Coronel D; García-Rivera EJ; Rivera DM; Arredondo-García JL; Dietze R; Perroud AP; Cortés M; Bonaparte M; Wang H; Pagnon A; Jantet-Blaudez F; Peñalosa LAR; Dayan G; Zambrano B; DiazGranados CA; Noriega F
Pediatr Infect Dis J; 2020 Oct; 39(10):961-968. PubMed ID: 32932330
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.
Villar LÁ; Rivera-Medina DM; Arredondo-García JL; Boaz M; Starr-Spires L; Thakur M; Zambrano B; Miranda MC; Rivas E; Dayan GH
Pediatr Infect Dis J; 2013 Oct; 32(10):1102-9. PubMed ID: 24067553
[TBL] [Abstract][Full Text] [Related]
18. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia.
Dorigatti I; Aguas R; Donnelly CA; Guy B; Coudeville L; Jackson N; Saville M; Ferguson NM
Vaccine; 2015 Jul; 33(31):3746-51. PubMed ID: 26051515
[TBL] [Abstract][Full Text] [Related]
19. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.
Scott LJ
Drugs; 2016 Sep; 76(13):1301-1312. PubMed ID: 27506852
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Mazara S; Vargas M; Brose M; Rauscher M; Tuboi S; Borkowski A; Wallace D
Lancet Infect Dis; 2018 Feb; 18(2):162-170. PubMed ID: 29122463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]